Jim Simons Clearside Biomedical, Inc. Transaction History
Renaissance Technologies LLC
- $63.4 Billion
- Q4 2024
A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Clearside Biomedical, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 721,789 shares of CLSD stock, worth $570,213. This represents 0.0% of its overall portfolio holdings.
Number of Shares
721,789
Previous 744,889
3.1%
Holding current value
$570,213
Previous $946,000
23.78%
% of portfolio
0.0%
Previous 0.0%
Shares
24 transactions
Others Institutions Holding CLSD
# of Institutions
50Shares Held
11.6MCall Options Held
24KPut Options Held
12.1K-
Vanguard Group Inc Valley Forge, PA2.81MShares$2.22 Million0.0% of portfolio
-
Act Capital Management, LLC Wayne, PA2.2MShares$1.74 Million3.43% of portfolio
-
Carmignac Gestion Paris, I01.93MShares$1.53 Million0.03% of portfolio
-
Black Rock Inc. New York, NY798KShares$630,5280.0% of portfolio
-
Geode Capital Management, LLC Boston, MA764KShares$603,6050.0% of portfolio
About Clearside Biomedical, Inc.
- Ticker CLSD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,190,700
- Market Cap $47.6M
- Description
- Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injec...